Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 13Gastrointestinal 10Gynecologic 9Genitourinary 9Breast 7Head & Neck 5CNS 4Sarcoma 3Other hematologic neoplasm 3Myeloid 3Endocrine 3NET 2Tumor-Agnostic 1Other neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 385Neoplasm Metastasis 111Carcinoma 14Adenocarcinoma 10Carcinoma, Squamous Cell 6Neoplasms, Unknown Primary 3Neoplasm, Residual 2Neoplasms, Second Primary 1Neoplasms by Site 1

Interventions

relatlimab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × Tumor-Agnostic × 90 days × Clear all
NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
1,482 enrolled 56 charts
Tumor-Agnostic

Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡